Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-09-04. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cell lungcancerchemotherapysmall cellnon small
  Phrases that lowered it: systemicthe trialwithin weekspatients whoaminotransferase
• Sponsor's past termination rate: 23.8% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 32.2% (raises risk) · Drug's FDA history
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 53 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 76.2% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 181 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Collaborators: 1 (raises risk) · Design
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer NCT02621398 · started 2016 · scored riskier than 87% of active trials completed
• Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT03029598 · started 2017 · scored riskier than 49% of active trials completed
• Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma NCT02748564 · started 2017 · scored riskier than 95% of active trials terminated
• Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT04387227 · started 2021 · scored riskier than 48% of active trials completed
• Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer NCT03095781 · started 2017 · scored riskier than 55% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.